	US 11,931,364 B2
	Modulation of the nitric oxide synthase pathway for oral health
Janet H. Southerland, Nashville, TN (US); and Pandu R. Gangula, Nashville, TN (US)
Assigned to Meharry Medical College, Nashville, TN (US)
Filed by Meharry Medical College, Nashville, TN (US)
Filed on Sep. 19, 2022, as Appl. No. 17/948,184.
Application 17/948,184 is a continuation of application No. 16/876,181, filed on May 18, 2020, abandoned.
Application 16/876,181 is a continuation of application No. 16/213,894, filed on Dec. 7, 2018, granted, now 10,688,098, issued on Jun. 23, 2020.
Application 16/213,894 is a continuation of application No. PCT/US2017/037031, filed on Jun. 12, 2017.
Claims priority of provisional application 62/349,415, filed on Jun. 13, 2016.
Prior Publication US 2023/0068887 A1, Mar. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/10 (2006.01); A61K 9/68 (2006.01); A61P 1/02 (2006.01); A61P 5/48 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 9/0056 (2013.01); A61K 9/0058 (2013.01); A61K 9/0063 (2013.01); A61K 9/06 (2013.01); A61K 9/10 (2013.01); A61P 1/02 (2018.01); A61P 5/48 (2018.01)]

20 Claims

1. A method of treating or reducing the likelihood of xerostomia in a subject, the method comprising administering a pharmaceutical composition to the subject, the pharmaceutical composition comprising:

an agent selected from tetrahydrobiopterin (BH₄), a prodrug of BH₄, or a pharmaceutically acceptable salt of any of the foregoing, in a therapeutically effective amount.